Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Zhou J. et al, (2025), EClinicalMedicine, 85
Reducing inequalities through greater diversity in clinical trials - As important for medical devices as for drugs and therapeutics.
Roope LSJ. et al, (2025), Contemp Clin Trials Commun, 45
Quantifying the impact of intervention on health outcomes: A tool for assessing incremental changes to life expectancy.
Singh S. et al, (2025), Value Health
Development and Validation of the Patient-Level Chinese Diabetes Outcome Model on Long-term Complications in Type 2 Diabetes: An Application of the Hong Kong Diabetes Register.
Lau ESH. et al, (2025), Diabetes Care, 48, 579 - 587
Inequality in COVID-19 vaccine acceptance and uptake: A repeated cross-sectional analysis of COVID vaccine acceptance and uptake in 13 countries.
Abel ZD. et al, (2025), Health Policy, 153
Inequalities in geographic barriers and patient representation in lymphoma clinical trials across England.
Jones DA. et al, (2025), Br J Haematol, 206, 531 - 540
Results of an Australian trial of an automated insulin delivery (AID) system and other studies support likely benefit of AID use for many Australian adults with type 1 diabetes.
Jenkins AJ. et al, (2025), Intern Med J, 55, 148 - 153
Using QALYs as an Outcome for Assessing Global Prediction Accuracy in Diabetes Simulation Models.
Dakin HA. et al, (2025), Med Decis Making, 45, 45 - 59
Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trial.
Halliday JA. et al, (2024), BMJ Open Diabetes Res Care, 12
Willingness to participate in placebo-controlled surgical trials of the knee.
Wall L. et al, (2024), Bone Joint J, 106-B, 1408 - 1415
Economic costs attributable to modifiable risk factors: an analysis of 24 million urban residents in China.
Xiong X. et al, (2024), BMC Med, 22
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes.
Zhao T. et al, (2024), Appl Health Econ Health Policy, 22, 861 - 869
Access to healthcare services during the COVID-19 pandemic: a cross-sectional analysis of income and user-access across 16 economically diverse countries.
Abel ZDV. et al, (2024), BMC Public Health, 24
Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge.
Altunkaya J. et al, (2024), Value Health, 27, 1338 - 1347
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Gao N. et al, (2024), Pharmacoeconomics, 42, 1017 - 1028
The impact of winning funding on researcher productivity, results from a randomized trial
Barnett A. et al, (2024), Science and Public Policy
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91).
Adler AI. et al, (2024), Lancet, 404, 145 - 155
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study.
Altunkaya J. et al, (2024), Lancet Diabetes Endocrinol, 12, 462 - 471